title: Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes - connection with inflammation.
abstract: OBJECTIVE
  To evaluate the status and diagnostic utility of antioxidant paraoxonase 1 (PON1) in gastroesophageal cancers.
  
  
  METHODS
  PON1's arylesterase/paraoxonase activities and phenotype were determined in 82 cancers and 57 controls, and related to clinicopathological features, anemia and cachexia coexistence, cholesterol levels, liver function panel, and inflammatory and angiogenic indices.
  
  
  RESULTS
  PON1's activities were decreased in cancer. Arylesterase activity correlated with cancer T and N stages, being an N1-independent predictor. Both activities correlated with transferrin, albumin, CRP and inflammation-based Glasgow Prognostic Score, and arylesterase activity also with interleukin-6 and midkine. Phenotype A (Q192 homozygotes) was associated with lower transferrin and higher TNF-alpha concentrations. PON1's arylesterase activity reflected anemia severity, being correlated with hemoglobin, hematocrit, and iron. PON1 arylesterase activity negatively correlated with alkaline phosphatase and gamma-glutamyl transferase, but not with bilirubin, aminotransferases, HDL or LDL cholesterol. PON1 moderately indicated cancer presence and regional metastasis.
  
  
  CONCLUSIONS
  PON1 activity decreases in gastroesophageal cancers and corresponds to inflammation severity and cancer-related anemia. PON1 decrease indicates lymph node metastasis, but its moderate predictive power does not recommend PON1 determination alone for clinical application.
authors.affiliation: Department of Medical Biochemistry, Wroclaw Medical University, Wroclaw, Poland. krzystek@bioch.am.wroc.pl
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Krzystek-Korpacka
authors.forename: Dorota
authors.initials: D
authors.lastname: Boehm
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Matusiewicz
authors.forename: Dorota
authors.initials: D
authors.lastname: Diakowska
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Grabowski
authors.forename: Andrzej
authors.initials: A
authors.lastname: Gamian
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000201:enzymology / Q000503:physiopathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000097:blood / Q000201:enzymology / Q000209:etiology; D043303:Aryldialkylphosphatase / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000201:enzymology / Q000503:physiopathology; D004938:Esophageal Neoplasms / Q000150:complications* / Q000201:enzymology* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000201:enzymology / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010257:Paraneoplastic Syndromes / Q000201:enzymology* / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D013274:Stomach Neoplasms / Q000150:complications* / Q000201:enzymology* / Q000473:pathology / Q000503:physiopathology
chemical_list: D043303:Aryldialkylphosphatase; C468406:PON1 protein, human